Innate Pharma S.A.
NASDAQ:IPHABiotechnology
Healthcare
$1.03 +1.91%
+$0.03 today
- Market cap
- $115.05M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
52W Low $1.17High $2.63
Volume 0.50M
Average 0.07M
Income Statement
Follow revenue through to earnings.
Revenue
$2.79M
FY 2025 · Annual
-77.9% YoYOperating Income
-$53.42M
FY 2025 · Annual
Net Income
-$49.18M
FY 2025 · Annual
Income Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.11M | 57.67M | 51.9M | 12.62M | 2.79M |
| Cost of Revenue | 47M | 51.66M | 56.02M | 51.98M | 0 |
| Gross Profit | (22.3M) | 6.01M | 5.62M | 12.62M | 2.79M |
| Gross Margin | -184.1% | 10.4% | 10.8% | 100.0% | 100.0% |
| Research & Development | 47M | 51.66M | 56.02M | 51.98M | 43.62M |
| Selling, General & Admin | 25.52M | 14.47M | 11.75M | 11.93M | 11M |
| Operating Expenses | 25.52M | 63.44M | 18.29M | 64.2M | 56.21M |
| Depreciation & Amortization | 4.6M | 45.41M | 5.09M | 1.99M | 5.09M |
| EBITDA | (43.23M) | (12.28M) | (1.84M) | (46.91M) | (43.65M) |
| EBITDA Margin | -356.9% | -21.3% | -3.5% | -371.7% | -1566.1% |
| Operating Income | (47.83M) | (57.43M) | (12.67M) | (51.58M) | (53.43M) |
| Operating Margin | -394.9% | -99.6% | -24.4% | -408.6% | -1916.9% |
| Interest Income | 327K | 546K | 3.18M | 2.44M | 1.32M |
| Interest Expense | 312K | 288K | 640K | 566K | 440K |
| Other Income / Expenses | 2.35M | (547K) | 5.1M | 2.1M | 4.25M |
| Income Before Tax | (45.48M) | (57.97M) | (7.57M) | (49.47M) | (49.18M) |
| Pre-Tax Margin | -375.5% | -100.5% | -14.6% | -392.0% | -1764.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (52.81M) | (58.1M) | (7.57M) | (49.47M) | (49.18M) |
| Net Margin | -436.0% | -100.7% | -14.6% | -392.0% | -1764.5% |
| EPS (Basic) | (0.57) | (0.73) | (0.09) | (0.61) | (0.53) |
| EPS (Diluted) | (0.57) | (0.73) | (0.09) | (0.61) | (0.53) |
| 79.54M | 79.59M | 84.11M | 81.05M | 89.42M | |
| 79.54M | 79.64M | 84.11M | 81.05M | 89.42M |
IPHA Earnings Waterfall · TTM
NASDAQ:IPHA · Revenue to Net Income
Key Ratios
EPS$-1.16
Gross Margin2321.8%
Net Margin-2064.7%
P/E Ratio-1.4
P/S Ratio124.0
Analysis
$15.4M of revenue converted into -$98.4M of net income for the selected period. Gross margin is 2321.8% and net margin is -2064.7%, showing how much revenue survives after costs and taxes. EPS is $-1.16, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| 6-K | 6-K filing | Nov 5, 2026 | |
| 6-K | 6-K filing | Oct 27, 2026 | |
| 6-K | 6-K filing | Oct 21, 2026 | |
| 6-K | 6-K filing | Oct 20, 2026 |
How much revenue does IPHA generate?
Innate Pharma S.A. (IPHA) reported $2.79M of revenue in fiscal 2025.
Is IPHA profitable?
Innate Pharma S.A. (IPHA) reported -$49.18M of net income, with a net margin of -1764.5%.
Continue the stock analysis
Jump to another research area for this company.